Status: Not yet recruiting
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Nuvation Bio Inc.Updated: Aug 11, 2026Locations: 5
Eligibility criteria
Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1... [+6]
Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross tot... [+6]